A Guide to DNA Damage Response and Innate Immunity
In this guide, we provide an overview of the DDR and innate immune pathway and describe Transcreener Assays and Assay Systems for key targets.
List view / Grid view
In this guide, we provide an overview of the DDR and innate immune pathway and describe Transcreener Assays and Assay Systems for key targets.
Using bioinformatics analyses, HK-CREs impact on cellular processes was studied, including their potential as housekeeping tumour suppressors.
22 December 2023 | By
Download now! Drug Target Review breaks down the potential of stem cells for personalised regenerative medicine, offering practical insights into their role in healthcare.
New findings about how RBM10 inhibits lung cancer growth offers potential for an anti-cancer drug and more personalised treatment.
Researchers have completely decoded the human Y chromosome, which may result in more effective treatment for digestive disorders.
Researchers have developed organoids with naturally occurring early-stage immune cells, which could lead to effective personalised treatment.
Cellulose nanofiber sheets enable analysis of EVs, and miRNAs within them, offering potential for cancer treatment and personalised medicine.
Scientists have discovered the motor protein dynein commands movement of cancer cells in soft tissue models, offering new clinical targets.
This ebook outlines Euretos’ approach to target discovery and indication expansion. Whilst also discussing data-driven target selection.
24 August 2023 | By Bio-Rad Laboratories Inc.
Watch our industry experts to learn about the tangible benefits and best practice of custom flow cytometry automation projects. You’ll discover how to reduce your challenges implementing tailored automation, controlling the quality of the data produced and improving the reliability of your data acquisition.
Human papillomavirus (HPV)-associated head and neck cancers, specifically head and neck squamous cell carcinoma (HNSCC), are on the rise worldwide. Yet, the factors contributing to these tumours and their varying responses to treatment remain poorly understood.
The potential of precision medicine requires a small shift in perspective, Patrick Short, CEO and co-founder of Sano Genetics, explains in this Q&A.
This article is the second part of Drug Target Review’s Izzy Wood’s discussion with Olivia Cavlan, Chief Corporate Development and Strategy Officer at Alchemab Therapeutics Ltd, exploring the role of AI in target discovery, its applications in personalised medicine, and the evolving landscape of pharmaceutical development.
Using a nanofluidic aptamer nanoarray to measure biomolecules including proteins, Japanese researchers are attempting to bridge the gap for precision medicine
14 June 2023 | By Sartorius
Watch our virtual panel, where you'll uncover the game-changing advantages of organoids over traditional 2D cultures. Our experts will explore the immense potential of organoids in oncology and immuno-oncology research.